Article Text
PDF
Summary
A 70-year-old patient with known hereditary haemorrhagictelangiectasia (HHT) was seen regularly in our outpatient clinic. He underwent multiple therapeutical interventions, including both surgical and medical, for the treatment of recurrent epistaxis without sustained success. Due to a concurrent diagnosis of idiopathic pulmonary fibrosis, treatment with the tyrosine kinase inhibitor nintedanib was initiated, after which point the patient reported a dramatic and unanticipated improvement in his epistaxis and skin telangiectasia. On the basis of this case report, we propose that nintedanib may be a potential treatment option for refractory epistaxis in HHT.
- Ear, nose and throat/otolaryngology
- Respiratory system
Statistics from Altmetric.com
Footnotes
Contributors EK-S: writing the manuscript, looking for the necessary data about the patient and in the literature. DH: correcting the manuscript mainly regarding to the nose symptoms and therapy of the disease; physician of the patient because of the nose bleed. TS: correcting the manuscript mainly regarding to the pulmonary symptoms of the disease. Physician of the patient because of the idiopathic pulmonary fibrosis. MBS: supervisor of the whole manuscript, further correcting, advising.
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.